Phase II Study on Neoadjuvant Therapy of AK104 Combined With Nab-paclitaxel/Carboplatin in Fertility Preserving Surgery

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 1, 2023

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2028

Conditions

Neoadjuvant ImmunotherapyCervical CancerFertility-sparing Surgery

Interventions

DRUG

AK104

AK104(10 mg/kg) d1,22

DRUG

Carboplatin

AUC=2 d1,8,15,22, 29, 36

DRUG

Nab paclitaxel

125mg／m2 d1,8,15,22,29,36

Trial Locations (1)

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors

lead

Xiaohua Wu

OTHER